The journal of international advanced otology · 2026
Dupilumab as a Therapeutic Option in Chronic Eustachian Tube Dysfunction and Chronic Rhinosinusitis with Nasal Polyposis: A Case-Based Observation.
СтатьяКлинический случайНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sudhoff Holger
Аннотация
BACKGROUND: To report the first documented case of complete resolution of refractory dilatory Eustachian tube dysfunction (ETD) following dupilumab treatment in patients with severe chronic rhinosinusitis with nasal polyposis (CRSwNP).
METHODS: Four consecutive patients with longstanding refractory dilatory ETD, severe CRSwNP, and asthma, unresponsive to multiple sinus and mastoid surgeries, were treated with dupilumab.
RESULTS: Dupilumab resulted in complete remission of both CRSwNP and dilatory ETD symptoms within 6 weeks. Audiometry and tubomanometry confirmed restoration of middle ear function.
CONCLUSION: Dupilumab may offer a novel therapeutic option for patients with dilatory ETD associated with type 2 inflammation. Further prospective studies are needed to assess its long-term efficacy.
METHODS: Four consecutive patients with longstanding refractory dilatory ETD, severe CRSwNP, and asthma, unresponsive to multiple sinus and mastoid surgeries, were treated with dupilumab.
RESULTS: Dupilumab resulted in complete remission of both CRSwNP and dilatory ETD symptoms within 6 weeks. Audiometry and tubomanometry confirmed restoration of middle ear function.
CONCLUSION: Dupilumab may offer a novel therapeutic option for patients with dilatory ETD associated with type 2 inflammation. Further prospective studies are needed to assess its long-term efficacy.